BioCryst (BCRX) Soars 10.8% on Swing to Profits

We recently published 10 Stocks Ending February With a Bang. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was one of the best performers on Friday.

BioCryst surged by 10.76 percent on Friday to close at $8.75 apiece, as investor sentiment was bolstered by its swing to profitability for the first time last year.

In an updated report, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said that it swung to a net income of $263.86 million last year from an $88.88 million net loss in 2024. Total revenues soared by 94 percent to $874.8 million from $450.7 million year-on-year, helped by the successful $243.3 million sale of its European Orladeyo business to Neopharmed Gentili. Orladeyo is a prescription oral medicine for preventing hereditary angioedema attacks in adults and children 12 years and older.

In the fourth quarter alone, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) incurred a $245.8 million net income, reversing a $26.79 million net loss in the same period a year earlier. Total revenues more than tripled to $406.5 million from $131.5 million year-on-year.

“2025 was fundamentally transformative for BioCryst. We achieved full-year profitability for the first time in the company’s history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the US since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve,” said BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) President and CEO Charlie Gayer.

alexkich/Shutterstock.com

For this year, the company is targeting to generate total revenues between $635 million and $660 million, of which around $625 million to $645 million will come from sales from Orladeyo.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.